<DOC>
	<DOC>NCT02842294</DOC>
	<brief_summary>The primary aim of this french multicenter national study is to assess and compare time to quality of life score deterioration (targeted dimensions : global health, fatigue and emotional functionning of EORTC QLQC30 according to the first line chemotherapy associated with bevacizumab in metastatic colorectal patients.</brief_summary>
	<brief_title>Cohort Study to Assess Impact of Chemotherapy Plus Bevacizumab on Health Related Quality of Life in First Line Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<criteria>age&gt; 18years metastatic colorectal cancer (non resectable) 1st chemotherapy including bevacizuman treatment contreindication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>bevacizumab</keyword>
	<keyword>health related quality of life</keyword>
</DOC>